https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-08-21 / Cancers (Basel) 2022 Aug;14(16)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-08-21 / Cancers (Basel) 2022 Aug;14(16)2022-08-21 00:00:002022-08-21 00:00:00Dendritic Cell Vaccines: A Promising Approach in the Fight against Ovarian Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-07-25 / Epigenomics 2022 Jul;14(14):865-886
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-07-25 / Epigenomics 2022 Jul;14(14):865-8862022-07-25 00:00:002022-07-25 00:00:00Leveraging epigenetics to enhance the efficacy of cancer-testis antigen: a potential candidate for immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-07-15 / Clin Cancer Res 2022 Jul;28(14):3053-3065
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-07-15 / Clin Cancer Res 2022 Jul;28(14):3053-30652022-07-15 00:00:002022-07-15 00:00:00An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-01-01 / J Immunother Cancer 2022 Jan;10(1)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-01-01 / J Immunother Cancer 2022 Jan;10(1)2022-01-01 00:00:002022-01-01 00:00:00Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-07-20 / Gynecol Oncol 2021 Sep;162(3):652-660
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-07-20 / Gynecol Oncol 2021 Sep;162(3):652-6602021-07-20 00:00:002023-03-14 09:44:20Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-05-21 / Exp Ther Med 2021 Jul;22(1):787
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-05-21 / Exp Ther Med 2021 Jul;22(1):7872021-05-21 00:00:002023-01-31 15:58:28Modulated electro-hyperthermia with weekly paclitaxel or cisplatin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: The KGOG 3030 trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-10-14 / Nat Commun 2020 10;11(1):5173
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-10-14 / Nat Commun 2020 10;11(1):51732020-10-14 00:00:002020-10-14 00:00:00Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-07-27 / J. Investig. Med. 2020 Jul;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-07-27 / J. Investig. Med. 2020 Jul;2020-07-27 00:00:002020-07-27 00:00:00Advanced clinical trials of dendritic cell vaccines in ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-07-13 / Immunol. Invest. 2020 Jul;:1-18
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-07-13 / Immunol. Invest. 2020 Jul;:1-182020-07-13 00:00:002020-07-13 00:00:00Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-04-22 / Curr. Opin. Biotechnol. 2020 Apr;65:190-196
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-04-22 / Curr. Opin. Biotechnol. 2020 Apr;65:190-1962020-04-22 00:00:002020-04-22 00:00:00Are dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer?
